{"id":505884,"date":"2020-09-08T15:46:01","date_gmt":"2020-09-08T15:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=505884"},"modified":"2020-09-08T15:46:01","modified_gmt":"2020-09-08T15:46:01","slug":"keratoconus-emerging-drugs-and-key-players-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/keratoconus-emerging-drugs-and-key-players-delveinsight_505884.html","title":{"rendered":"Keratoconus Emerging drugs and Key Players | DelveInsight"},"content":{"rendered":"
\"Keratoconus<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
Keratoconus Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Keratoconus market. A detailed picture of the Keratoconus pipeline landscape is provided, which includes the disease overview and Keratoconus treatment guidelines. <\/div>\n

Keratoconus is an eye disorder characterized by progressive thinning and changes in the shape of the cornea.<\/p>\n

The pipeline of KC possess only one key player, which is iVeena Delivery Systems. The dynamics of KC market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapy is expected during the forecast period of 2020-2030.<\/p>\n

IVMED-80 is the first twice-daily, eye-drop, non-surgical, non-UV light treatment for medical crosslinking of the cornea being developed by iVeena Delivery Systems. The drug, with its copper-based formulation, is reportedly the first eye drop designed to treat KC without the need for adjunctive laser treatment or surgical intervention. IVMED-80’s mechanism of action centers on enhancing the activity of lysyl oxidase (LOX) – the enzyme responsible for corneal collagen crosslinking, and also known to be associated with KC and copper, which is a co-factor of LOX, is the active ingredient of the drug. The FDA granted orphan drug designation for IVMED-80 for the treatment of KC. In February 2019, the company announced the commencement of a 36 patient phase I\/IIa pilot clinical study for the treatment of mild and moderate KC (IVMED-80) and presented an abstract of the trial in the 2020 ARVO Annual Meeting. Final results of the trial are expected at the end of August 2020. Currently, this therapy is in phase I\/II a clinical developmental trial for mild and moderate form of KC.<\/p>\n

Keratoconus Marketed therapies<\/strong><\/a><\/p>\n

    \n
  1. Photrexa Viscous and Photrexa: Glaukos\/Avedro<\/li>\n
  2. CE Marked Riboflavin Formulations: Avedro\/ Glaukos Corporation<\/li>\n
  3. Ricrolin: Sooft Italia<\/li>\n
  4. Collagex Riboflavin: Lightmed_OptiMed<\/li>\n
  5. Peschke Riboflavin Solutions: Peschke Meditrade GmbH<\/li>\n<\/ol>\n

    Keratoconus Emerging Therapies<\/strong><\/a><\/p>\n

    IVMED-80: iVeena Delivery Systems<\/strong><\/p>\n

     <\/p>\n

    Request for sample pages<\/strong><\/a>
    Table of contents<\/strong><\/a><\/p>\n

    1. Report Introduction<\/span><\/p>\n

    2. Keratoconus <\/span><\/p>\n

    2.1. Overview<\/span><\/p>\n

    2.2. History <\/span><\/p>\n

    2.3. Keratoconus Symptoms<\/span><\/p>\n

    2.4. Causes<\/span><\/p>\n

    2.5.Pathophysiology<\/span><\/p>\n

    2.6. Keratoconus Diagnosis <\/span><\/p>\n

    2.6.1. Diagnostic Guidelines<\/span><\/p>\n

    3. Keratoconus Current Treatment Patterns<\/span><\/p>\n

    3.1. Keratoconus Treatment Guidelines<\/span><\/p>\n

    4. Keratoconus – DelveInsight’s Analytical Perspective<\/span><\/p>\n

    4.1. In-depth Commercial Assessment<\/span><\/p>\n

    4.1.1. Keratoconus companies collaborations, Licensing, Acquisition -Deal Value Trends<\/span><\/p>\n

    4.1.1.1. Assessment Summary<\/span><\/p>\n

    4.1.2. Keratoconus Collaboration Deals<\/span><\/p>\n

    4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/span><\/p>\n

    4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/span><\/p>\n

    4.1.2.3. Keratoconus Acquisition Analysis<\/span><\/p>\n

    5. Therapeutic Assessment<\/span><\/p>\n

    5.1. Clinical Assessment of Pipeline Drugs <\/span><\/p>\n

    5.1.1. Assessment by Phase of Development<\/span><\/p>\n

    5.1.2. Assessment by Product Type (Mono \/ Combination)<\/span><\/p>\n

    5.1.2.1. Assessment by Stage and Product Type<\/span><\/p>\n

    5.1.3. Assessment by Route of Administration<\/span><\/p>\n

    5.1.3.1. Assessment by Stage and Route of Administration<\/span><\/p>\n

    5.1.4. Assessment by Molecule Type<\/span><\/p>\n

    5.1.4.1. Assessment by Stage and Molecule Type<\/span><\/p>\n

    5.1.5. Assessment by MOA<\/span><\/p>\n

    5.1.5.1. Assessment by Stage and MOA<\/span><\/p>\n

    5.1.6. Assessment by Target<\/span><\/p>\n

    5.1.6.1. Assessment by Stage and Target<\/span><\/p>\n

    6. Keratoconus Late Stage Products (Phase-III)<\/span><\/p>\n

    7. Keratoconus Mid Stage Products (Phase-II)<\/span><\/p>\n

    8. Early Stage Products (Phase-I)<\/span><\/p>\n

    9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n

    10. Inactive Products<\/span><\/p>\n

    11. Dormant Products<\/span><\/p>\n

    12. Keratoconus Discontinued Products<\/span><\/p>\n

    13. Keratoconus Product Profiles<\/span><\/p>\n

    13.1. Drug Name: Company <\/span><\/p>\n

    13.1.1. Product Description<\/span><\/p>\n

    13.1.1.1. Product Overview<\/span><\/p>\n

    13.1.1.2. Mechanism of action<\/span><\/p>\n

    13.1.2. Research and Development<\/span><\/p>\n

    13.1.2.1. Clinical Studies<\/span><\/p>\n

    13.1.3. Product Development Activities<\/span><\/p>\n

    13.1.3.1. Collaboration<\/span><\/p>\n

    13.1.3.2. Agreements<\/span><\/p>\n

    13.1.3.3. Acquisition <\/span><\/p>\n

    13.1.3.4. Patent Detail<\/span><\/p>\n

    13.1.4. Tabulated Product Summary<\/span><\/p>\n

    13.1.4.1. General Description Table<\/span><\/p>\n

    14. Keratoconus Key Companies<\/p>\n

    15. Keratoconus Key Products<\/span><\/p>\n

    16. Dormant and Discontinued Products<\/span><\/p>\n

    16.1. Dormant Products<\/span><\/p>\n

    16.1.1. Reasons for being dormant<\/span><\/p>\n

    16.2. Discontinued Products <\/span><\/p>\n

    16.2.1. Reasons for the discontinuation<\/span><\/p>\n

    17. Keratoconus Unmet Needs<\/span><\/p>\n

    18. Keratoconus Future Perspectives<\/span><\/p>\n

    19. Keratoconus Analyst Review  <\/span><\/p>\n

    20. Appendix<\/span><\/p>\n

    21. Report Methodology<\/span><\/p>\n

    Media Contact<\/span>
    Company Name:<\/strong>     DelveInsight<\/a>
    Contact Person:<\/strong> Priya Maurya
    Email:<\/strong>     Send Email<\/a>
    Phone:<\/strong> +919650213330
    City:<\/strong> Albany
    State:<\/strong> New York
    Country:<\/strong> United States
    Website:<\/strong>     https:\/\/www.delveinsight.com\/<\/a><\/p>\n

    <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

    DelveInsight Business Research LLP Keratoconus Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Keratoconus market. A detailed picture of the Keratoconus pipeline landscape is provided, which includes the disease … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-505884","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/505884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=505884"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/505884\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=505884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=505884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=505884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}